boi568
8 minutes ago
There is no regulatory "sufficiency" test, other than being better than the standard of care, if one exists. The article makes the case that blarcamesine is better than any approved AD drug. The FDA employs a risk/benefit analysis, and you want your drug candidate to more than offset any risks with